抗冠状病毒药物研究进展  

Research progress on anti-coronavirus drugs

作　　者：秦聖乐 王玉涛[1] 蔡雪君 王新华[1] 杨子峰[1] QIN Shengle;WANG Yutao;CAI Xuejun;WANG Xinhua;YANG Zifeng(State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510182,China)

机构地区：[1]广州医科大学附属第一医院,广州呼吸健康研究院,呼吸疾病国家重点实验室,广州510182

出　　处：《中国比较医学杂志》2022年第6期105-110,共6页Chinese Journal of Comparative Medicine

基　　金：国家重点研发计划(2020YFA0708002);国家自然科学基金(82074311)。

摘　　要：新冠疫情持续至今,对人类健康、经济及社会发展造成深远影响。由于其感染性强,传播速度快,以及变异株的不断出现,导致防控难度极大。药物是防治病毒性感染疾病的重要措施之一,目前尚无批准用于临床的抗新冠病毒特效药物。根据冠状病毒的致病特点和发病机制,已有较多关于抗病毒药物靶点研究,本文对以冠状病毒刺突蛋白,核糖核酸(ribonucleic acid,RNA)依赖性RNA聚合酶,3C样蛋白酶(3C-like proteinase,3CLPro)等为靶点的药物研究以及抗冠状病毒中药的体内研究现状进行综述,为冠状病毒感染,尤其是新冠病毒感染防治提供药效学依据,并为其后续的临床应用提供参考。The ongoing coronavirus disease 2019(COVID-19)pandemic is having a profound impact on human health,economics,and social development.This disease has been extremely difficult to prevent and control because of its strong infectivity and rapid transmission,along with the constant emergence of mutant strains of the causative virus,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).Drugs are an important measure for the prevention and treatment of viral infectious diseases.At present,there are no specific anti-SARS-CoV-2 drugs approved for clinical use.There have been many studies on antiviral drug targets guided by present understanding of the characteristics and mechanism of coronavirus pathogenesis.This review discusses the current research status of drugs targeting coronavirus Spike protein,ribonucleic acid(RNA)-dependent RNA polymerase and 3C-like proteinase,as well as Traditional Chinese Medicine against coronaviruses;it details the pharmacodynamic basis for the prevention and treatment of coronaviruses,especially SARS-CoV-2,by these drugs and provides a reference for their subsequent clinical application.

关 键 词：冠状病毒 抗病毒药物 作用靶点 

分 类 号：R-33[医药卫生]